KalVista Pharmaceuticals (KALV) Capital Expenditures (QoQ) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -57.02% |
| Oct 31, 2024 | 1.56% |
| Jul 31, 2024 | 125.40% |
| Apr 30, 2024 | -188.11% |
| Jan 31, 2024 | 14,200.00% |
| Oct 31, 2023 | -66.67% |
| Jul 31, 2023 | -91.30% |
| Apr 30, 2023 | 360.00% |
| Jan 31, 2023 | -92.19% |
| Oct 31, 2022 | -79.13% |
| Jul 31, 2022 | 969.77% |
| Apr 30, 2022 | -57.43% |
| Jan 31, 2022 | -43.26% |
| Oct 31, 2021 | 24.04% |
| Jul 31, 2021 | 769.70% |
| Apr 30, 2021 | 135.71% |
| Jan 31, 2021 | 7.69% |
| Oct 31, 2020 | -40.91% |
| Jul 31, 2020 | 175.00% |
| Oct 31, 2019 | 16.33% |
| Jul 31, 2019 | -64.36% |
| Apr 30, 2019 | 1,275.00% |
| Jan 31, 2019 | -90.95% |
| Oct 31, 2018 | -60.88% |
| Jul 31, 2018 | -47.88% |
| Apr 30, 2018 | 495.60% |
| Jan 31, 2018 | 256.86% |
| Oct 31, 2017 | -53.64% |
| Jul 31, 2017 | 1,471.43% |
| Apr 30, 2017 | 16.67% |
| Jan 31, 2017 | -66.67% |
| Oct 31, 2016 | -58.14% |
| Mar 31, 2016 | -51.45% |
| Dec 31, 2015 | 1,704.76% |
| Sep 30, 2015 | -73.42% |
| Jun 30, 2015 | -56.11% |
| Sep 30, 2014 | -90.67% |
| Jun 30, 2014 | 7,400.00% |